Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 5 | 2016 | 1802 | 0.410 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2013 | 22 | 0.380 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2013 | 37 | 0.380 |
Why?
|
| Receptor, Notch1 | 3 | 2018 | 78 | 0.360 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2013 | 237 | 0.350 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2013 | 354 | 0.320 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 588 | 0.310 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 620 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 2 | 2016 | 735 | 0.130 |
Why?
|
| Ephrin-B2 | 1 | 2016 | 9 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 126 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2018 | 174 | 0.130 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2016 | 33 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 3 | 2018 | 978 | 0.120 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2016 | 63 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 816 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 27 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 57 | 0.110 |
Why?
|
| Anilides | 1 | 2014 | 52 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2016 | 823 | 0.100 |
Why?
|
| Gene Dosage | 1 | 2015 | 435 | 0.100 |
Why?
|
| Biomarkers, Tumor | 3 | 2016 | 1586 | 0.100 |
Why?
|
| Neoplasms | 3 | 2018 | 2980 | 0.100 |
Why?
|
| Pyridines | 1 | 2014 | 258 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 57 | 0.090 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2013 | 62 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2016 | 1000 | 0.090 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2012 | 13 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2013 | 79 | 0.090 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2012 | 46 | 0.090 |
Why?
|
| Pyrimidinones | 1 | 2012 | 62 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 479 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 469 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1267 | 0.090 |
Why?
|
| Pyridones | 1 | 2012 | 139 | 0.080 |
Why?
|
| Mutation | 2 | 2016 | 6070 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 747 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 635 | 0.080 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 1026 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 720 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 613 | 0.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2009 | 191 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 1367 | 0.060 |
Why?
|
| Prognosis | 4 | 2018 | 4855 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 2 | 2018 | 174 | 0.060 |
Why?
|
| Mucin-1 | 1 | 2004 | 32 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 1932 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 1406 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2016 | 699 | 0.050 |
Why?
|
| Carcinoma | 1 | 2004 | 283 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1332 | 0.050 |
Why?
|
| Male | 8 | 2018 | 64375 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 383 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 902 | 0.040 |
Why?
|
| Middle Aged | 6 | 2018 | 28305 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2016 | 1481 | 0.040 |
Why?
|
| Mice | 5 | 2016 | 18153 | 0.040 |
Why?
|
| Aged | 5 | 2018 | 20818 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 714 | 0.030 |
Why?
|
| Animals | 6 | 2016 | 33660 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2018 | 362 | 0.030 |
Why?
|
| Humans | 9 | 2018 | 130071 | 0.030 |
Why?
|
| Female | 8 | 2018 | 70243 | 0.030 |
Why?
|
| Adult | 5 | 2018 | 31012 | 0.030 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2015 | 35 | 0.030 |
Why?
|
| Jagged-1 Protein | 1 | 2015 | 51 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 961 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 777 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1605 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2014 | 65 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 77 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 799 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 322 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1069 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2015 | 287 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 112 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2015 | 358 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 227 | 0.020 |
Why?
|
| Survival Rate | 1 | 2018 | 2110 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 1592 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1391 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 336 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2015 | 4645 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 126 | 0.020 |
Why?
|
| Half-Life | 1 | 2012 | 148 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 4642 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 479 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 303 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2289 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 723 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 706 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2009 | 40 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1803 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 80 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2012 | 287 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5169 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 2010 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 5038 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2016 | 12831 | 0.020 |
Why?
|
| Pancreatectomy | 1 | 2009 | 147 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1829 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 1240 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 217 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1588 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 630 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 4461 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 3713 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 6169 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 1214 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 1278 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3406 | 0.010 |
Why?
|
| United States | 2 | 2012 | 11890 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2004 | 226 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2004 | 198 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 1282 | 0.010 |
Why?
|
| Risk Factors | 1 | 2016 | 10950 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 6763 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 3676 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2016 | 17541 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 9981 | 0.010 |
Why?
|